Merck & Company Inc. (new) ($MRK) Stock Forecast: Down 9.1% Today

What is Merck & Company Inc. (new)?

Merck (MRK) is a pharmaceutical giant known for its innovative healthcare solutions and products. Today, the stock experienced a significant bearish movement in the market.

Why is Merck & Company Inc. (new) going down?

MRK stock is down 9.1% on Jul 30, 2024 18:46

• Merck's Gardasil sales were impacted by China's corruption crackdown, leading to a slowdown in shipments and spooking investors.
• The company's lowered adjusted EPS guidance contributed to the negative sentiment among investors, causing the stock to slide.
• Amidst a mixed day for U.S. equities, Merck stood out with a notable 8% drop, contrasting with the surge in financials and energy stocks.
• The overall sentiment in the biotech sector, to which Merck belongs, was not favorable, as evidenced by the 10% decline in Merck's stock price.

MRK Price Chart

MRK Technical Analysis

MRK News

China corruption crackdown hits Merck''s Gardasil sales, spooking investors

China’s recent effort to crack down on healthcare corruption has spurred a slowdown in Gardasil shipments, according to Merck CEO Rob Davis. On Tuesday, Davis told investors that China''s corruption work led to criminal charges against “a senior scientific representative” related to a Covid-19 vaccine, impacting immunization efforts in the

https://endpts.com/china-corruption-crackdown-hits-mercks-gardasil-sales-spooking-investors/

Chart of the Day: Merck

Merck is down 10% today. The Investment Committee discuss the biotech sector.

https://www.cnbc.com/video/2024/07/30/chart-of-the-day-merck.html

Top Stock Movers Now: PayPal, JetBlue, Merck, Procter & Gamble, and More

U.S. equities were mixed at midday with earnings reports in focus and ahead of a Fed decision on interest rates tomorrow.

https://www.investopedia.com/top-stock-movers-now-paypal-jetblue-merck-procter-and-gamble-and-more-8685985

Merck Stock Slides on Lowered Adjusted EPS Guidance

Shares of Merck & Co. tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.

https://www.investopedia.com/merck-stock-slides-on-lowered-adjusted-eps-guidance-8685894

Nasdaq 100: Tech Stocks Decline as Investors Await Federal Reserve’s Policy Decision

Financials and energy stocks surge while tech declines. JetBlue soars 20% on unexpected profit; Pfizer up 1.6% on strong Q2 results. Merck drops 8% on weak guidance.

https://www.fxempire.com/forecasts/article/nasdaq-100-tech-stocks-decline-as-investors-await-federal-reserves-policy-decision-1449814

Trending Today

XRP ($XRP) Crypto Forecast: Up 19.8% Today

Cardano ($ADA) Crypto Forecast: Up 6.1% Today

Ethereum ($ETH) Crypto Forecast: Up 7.2% Today

Solana ($SOL) Crypto Forecast: Up 8.3% Today

Memecoin ($MEME) Crypto Forecast: Up 5.9% Today

Litecoin ($LTC) Crypto Forecast: Up 6.0% Today

Pepe ($PEPE) Crypto Forecast: Up 10.2% Today

Starknet ($STRK) Crypto Forecast: Up 10.3% Today

Optimism ($OP) Crypto Forecast: Up 26.3% Today

Arbitrum ($ARB) Crypto Forecast: Up 16.9% Today

Merck & Company Inc. (new) Price History

25.03.2024 - MRK Stock was up 5.2%

• Merck (MRK) showed a significant upward trend in trading.
• In Q1, the company exceeded expectations with its adjusted earnings.
• The strong sales of Keytruda and vaccines contributed to the positive earnings, prompting an improved company outlook.
• Investor confidence and optimism in Merck's growth and product range were evident in the market's positive response.

02.07.2023 - MRK Stock was up 1.5%

• Merck posted a narrower-than-expected quarterly loss and exceeded sales estimates, which likely contributed to the bullish movement in the stock.
• The positive performance of Keytruda, with sales surging 19%, lifted Merck's revenue and outlook, further driving the bullish sentiment.
• Weaker-than-expected earnings from other pharmaceutical companies, such as Pfizer, may have negatively impacted the broader index but did not affect Merck's bullish movement.
• The company's commitment to prioritizing investments in its business and growing pipeline also added to the positive sentiment surrounding Merck.

26.05.2023 - MRK Stock was down 2.4%

• MRK had a strong bearish movement despite the opening of their new headquarters in Rahway.
• Naviter Wealth LLC increased their stock holdings in MRK, but Citigroup upgraded MRK and boosted their target price for the current fiscal year.
• The S&P and NASDAQ indices snapped their 3-day losing streaks, with MRK being one of the Dow 30 leaders for the day.
• There is no clear indication from the provided news articles that could have caused the bearish movement in MRK, but it could be attributed to overall market trends or other external factors not mentioned in the articles.

02.07.2023 - MRK Stock was up 1.0%

• Merck's stock had a strong bullish movement today, despite reporting a quarterly loss due to its acquisition of Prometheus Biosciences.
• The positive market movement could be attributed to the company's strong sales of Keytruda and Gardasil, which exceeded expectations.
• The bullish trend may also be influenced by investors' assessment of mixed earnings from other pharmaceutical heavyweights like Pfizer.
• The overall market sentiment, with the Dow stocks Merck and Caterpillar rising after reporting strong quarterly earnings, could have contributed to the bullish movement of Merck's stock.

30.04.2024 - MRK Stock was down 0.6%

• Merck's agreement to acquire EyeBio for up to $3 billion may have raised concerns among investors about the company's financial health and the potential dilution of shareholder value.
• The market may have reacted negatively to the news of Merck's scientific collaboration deal with Korea's KAIST, as investors might be uncertain about the immediate benefits and long-term implications of this partnership.
• The Chronic Kidney Disease market forecast and the list of companies involved in this sector may have signaled increased competition for Merck, leading to a bearish sentiment among investors.
• Overall, the combination of these developments could have contributed to the bearish movement in Merck's stock today, as investors reevaluated the company's strategic decisions and competitive positioning in the market.

27.02.2024 - MRK Stock was up 5.2%

• Merck's stock experienced a strong bullish trend following the FDA approval of their new treatment for a deadly lung condition, Winrevair, which holds promising market potential.
• The positive outlook towards Merck was also supported by the FDA approval for their drug targeting pulmonary arterial hypertension in adults, demonstrating the company's dedication to creating impactful healthcare solutions.
• The general market recovery and the upsurge in S&P 500 index also played a role in the bullish movement of Merck's stock, reflecting a broader optimism among investors towards the pharmaceutical industry.
• With these recent milestones and endorsements, Merck's innovative approach to healthcare solutions is expected to fuel further growth and investor confidence in the company's future prospects.

06.08.2023 - MRK Stock was down 3.8%

• The bearish movement in MRK's stock could be attributed to the following factors:
• 1. Market sentiment: The overall bearish sentiment in the Asian markets, as mentioned in an article from WNYT, may have influenced the decline in MRK's stock price. Investors' concerns about inflationary pressures and central banks' interest rate hikes could have contributed to the negative market movement.
• 2. Insider selling: an article from EIN News Pharmaceuticals highlights that MML Investors Services LLC decreased its stock position in MRK. This insider selling activity might have signaled a lack of confidence in the company's future prospects, leading to a bearish sentiment among other investors.
• 3. Cancer treatment competition: an article from Benzinga discusses the pharmaceutical industry's ongoing battle against cancer. The mention of Moderna Inc (MRNA) and Merck (MRK) collaborating on a late-stage study for a skin-cancer combination treatment could have raised concerns about potential competition for MRK's existing cancer therapies. This news might have impacted investor sentiment and contributed to the bearish movement in MRK's stock.
• 4. Long-term follow-up data: an article from Wallstreet:Online mentions the publication of long-term follow-up data for GARDASIL9, a vaccine developed by Merck. While this news is positive, it might not have had an immediate impact on the stock price. Therefore, it is less likely to be a significant factor in the bearish movement observed today.
• Overall, the bearish movement in MRK's stock today could be attributed to the combination of market sentiment, insider selling, and potential competition in the cancer treatment space.

30.06.2024 - MRK Stock was down 5.3%

• Merck reported strong Q2 earnings with revenue and EPS beating expectations, driven by robust sales of Keytruda, a cancer immunotherapy drug.
• Despite the positive earnings report, the market movement for MRK today could be attributed to concerns over acquisition costs impacting the annual profit forecast, leading to a bearish sentiment among investors.
• The overall market sentiment was slightly positive with US futures rising ahead of major earnings reports and the Federal Reserve meeting, indicating a cautious optimism among investors.
• The news about CrowdStrike dropping in premarket trading due to potential damages sought by Delta Air Lines could have added to the negative sentiment in the market, impacting MRK's stock price.

30.06.2024 - MRK Stock was down 9.5%

• Merck & Co's stock experienced a strong bearish movement today after the company lowered its full-year adjusted profit guidance, causing a significant drop in share price.
• Despite beating earnings per share and revenue expectations for Q2 2024, the market reacted negatively to the lowered guidance for the future, leading to the stock decline.
• Recommendation to buy Merck on the post-earnings dip may indicate a potential opportunity for investors looking at the long-term prospects of the company beyond the current market reaction.
• The broader market sentiment, with investors awaiting the Federal Reserve's policy decision, likely added to the volatility in tech stocks like Merck, contributing to the bearish movement.

30.06.2024 - MRK Stock was down 9.1%

• Merck's Gardasil sales were impacted by China's corruption crackdown, leading to a slowdown in shipments and spooking investors.
• The company's lowered adjusted EPS guidance contributed to the negative sentiment among investors, causing the stock to slide.
• Amidst a mixed day for U.S. equities, Merck stood out with a notable 8% drop, contrasting with the surge in financials and energy stocks.
• The overall sentiment in the biotech sector, to which Merck belongs, was not favorable, as evidenced by the 10% decline in Merck's stock price.

30.06.2024 - MRK Stock was down 9.3%

• Merck & Co exceeded analyst estimates in earnings per share and revenue for Q2 2024, demonstrating robust financial performance.
• The company reduced its adjusted earnings guidance for full-year 2024, causing investor worries and a decline in the market.
• While the Healthcare sector gained, the Technology sector had mixed outcomes. Merck's decline amid positive news from Healthcare sector suggests internal factors affecting its stock performance.
• The Technology sector's variability, including companies like Nvidia facing declines, implies market forces or competitive pressures influencing investor sentiment and contributing to Merck's downturn.

30.06.2024 - MRK Stock was down 10.2%

• Merck (MRK) swung to profit in Q2 on higher revenues, beating earnings expectations. This positive financial performance should have been a bullish indicator for the stock.
• Despite the strong earnings report, Merck (MRK) experienced a notable bearish movement in the market. This could be attributed to potential concerns about acquisition costs impacting the annual profit forecast.
• The mixed results in the Technology sector and the slight dip in major tech players like Nvidia (NVDA) could have influenced overall market sentiment, indirectly affecting Merck's stock price.
• The robust performance of companies like AbbVie (ABBV) in the Healthcare sector might have diverted investor attention away from Merck, contributing to the bearish movement in MRK's stock.